Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02951156 · ClinicalTrials.gov registry record · Phase 3
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 29
- Enrollment target
NCT02951156 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 29 participants.
The verdict
NCT02951156, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 29 participants
- Enrollment target
Study Summary
Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents for the treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL).
Interventions
- BIOLOGICAL Rituximab
- BIOLOGICAL Avelumab
- DRUG Bendamustine
- BIOLOGICAL Utomilumab
- OTHER Azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-12-16 |
| Est. Completion | 2019-12-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02951156
The ClinicalTrials.gov registry entry for NCT02951156 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rituximab is the first listed.
NCT02951156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02951156 about?
NCT02951156 is a clinical study titled "Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)". Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents for the treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL).
What is the current status of trial NCT02951156?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 29 participants. The study started on 2016-12-16. Estimated completion is 2019-12-02.
What interventions are being tested in trial NCT02951156?
The interventions under investigation include: Rituximab (BIOLOGICAL), Avelumab (BIOLOGICAL), Bendamustine (DRUG), Utomilumab (BIOLOGICAL), Azacitidine (OTHER).
Who is sponsoring clinical trial NCT02951156?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.